tella Inc. | Cash Flow

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
23,225.00
330,482.00
1,013,231.00
852,774.00
633,621.00
Depreciation, Depletion & Amortization
165,630.00
185,553.00
211,757.00
138,841.00
6,066.00
Other Funds
-
1,360.00
-
2,490.00
-
Funds from Operations
29,594.00
129,433.00
377,704.00
492,217.00
256,257.00
Changes in Working Capital
34,268.00
9,449.00
9,290.00
73,301.00
303,515.00
Net Operating Cash Flow
4,674.00
119,984.00
386,994.00
565,518.00
47,258.00
Capital Expenditures
175,683.00
201,350.00
309,889.00
35,217.00
155,556.00
Sale of Fixed Assets & Businesses
5,500.00
-
-
11,729.00
18,251.00
Purchase/Sale of Investments
100,000.00
249,166.00
80,946.00
372,368.00
3,853.00
Net Investing Cash Flow
314,778.00
523,441.00
371,383.00
374,555.00
360,921.00
Cash Dividends Paid - Total
10,092.00
47.00
16.00
-
-
Issuance/Reduction of Debt, Net
232,993.00
34,964.00
101,075.00
1,077.00
335,356.00
Net Financing Cash Flow
359,661.00
1,312,794.00
87,041.00
1,412.00
1,122,185.00
Net Change in Cash
49,557.00
669,369.00
845,418.00
189,551.00
808,522.00
Free Cash Flow
129,688.00
311,929.00
634,303.00
600,735.00
87,648.00
Net Assets from Acquisitions
-
70,966.00
17,919.00
-
230,560.00
Other Sources
39.00
-
88,054.00
25,675.00
10,800.00
Change in Capital Stock
136,760.00
1,346,445.00
14,050.00
-
1,457,542.00
Other Uses
44,634.00
1,959.00
50,683.00
-
-

About tella

View Profile
Address
Mitsuihanagiri Building, 1/F
Tokyo Tokyo 160
Japan
Employees -
Website http://www.tella.jp
Updated 09/14/2018
tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It also offers technology and know-how to medical institutions such as university hospitals and national hospitals. It operates through the following business segments: Cell Medicine, Medical Support, and Pharmaceuticals.